This is a working overview of IGF-1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The sisters also released a book, Kardashian Konfidential, in November 2010. In February 2011, Kardashian and her husband released a unisex fragrance called "Unbreakable." In May 2011, Kardashian and her sisters announced the release of their first novel. Prior to publication, the sisters requested help with naming their book. The winner was offered a cameo appearance in the novel. In July 2011, it was announced that the winning title was Dollhouse. In October 2012, Kardashian and Odom released a second unisex fragrance, "Unbreakable Joy," inspired by the holiday season. Kardashian's radio show, The Mix Up With Khloé Kardashian Odom, was a "one-hour, commercial-free show where Kardashian will take requests, chat with her celebrity friends, and more during the Mavericks' season while she's in Dallas with her husband Lamar Odom." It aired on January 30, 2012. She later made an appearance on the MTV television series Punk'd with Kelly Osbourne and Miley Cyrus in February 2012. In October 2012, Kardashian and Mario Lopez were confirmed as the co-hosts of the second season of the American version of The X Factor. It was confirmed on April 22, 2013, that Kardashian will not return to co-host The X Factor for its third season. On March 26, 2014, E! announced a Keeping Up with the Kardashians spin-off series titled Kourtney & Khloé Take the Hamptons. The Hamptons follows Kourtney, Khloé, and Scott Disick as they relocate to The Hamptons while the girls work on the New York Dash store plus open a pop-up store.
=== Australian National University === In the original design of the city of Canberra, the architect, Walter Burley Griffin, had provided for a university and had set aside land for it at the base of Black Mountain, where it would ultimately be built. Sir David Rivett chaired a committee constituted to investigate the proposed medical research institute, how much it would cost, and how it would affect existing and proposed institutions. Florey mailed Rivett a 19-page proposal on 7 April 1945. Florey envisaged a funding body in Australia similar to the Medical Research Council in the UK. The institute would be headed by a director, and have about one hundred staff, which he calculated would cost about £100,000 (equivalent to £3,732,000 in 2025). His estimate of the cost of the building was too low; Florey estimated that £240,000 (equivalent to £8,956,000 in 2025) would be enough for a building for 60 researchers, but it would eventually cost almost four times as much.
Originally, seven such proteins were discovered. Of these, six (BMP2 through BMP7) belong to the Transforming growth factor beta superfamily of proteins. BMP1 is a metalloprotease. Since then, thirteen more BMPs, all of which are in the TGF-beta family, have been discovered, bringing the total to twenty. The current nomenclature only recognizes 13, as many others are put under the growth differentiation factor naming instead.
BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen. In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8-acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.
Sources: en.wikipedia.org
Hsp70 seems to be able to participate in disposal of damaged or defective proteins. Interaction with CHIP (Carboxyl-terminus of Hsp70 Interacting Protein)–an E3 ubiquitin ligase–allows Hsp70 to pass proteins to the cell's ubiquitination and proteolysis pathways. Finally, in addition to improving overall protein integrity, Hsp70 directly inhibits apoptosis. One hallmark of apoptosis is the release of cytochrome c, which then recruits Apaf-1 and dATP/ATP into an apoptosome complex. This complex then cleaves procaspase-9, activating caspase-9 and eventually inducing apoptosis via caspase 3 activation. Hsp70 inhibits this process by blocking the recruitment of procaspase-9 to the Apaf-1/dATP/cytochrome c apoptosome complex. It does not bind directly to the procaspase-9 binding site, but likely induces a conformational change that renders procaspase-9 binding less favorable. Hsp70 is shown to interact with Endoplasmic reticulum stress sensor protein IRE1alpha thereby protecting the cells from ER stress - induced apoptosis. This interaction prolonged the splicing of XBP-1 mRNA thereby inducing transcriptional upregulation of targets of spliced XBP-1 like EDEM1, ERdj4 and P58IPK rescuing the cells from apoptosis. Other studies suggest that Hsp70 may play an anti-apoptotic role at other steps, but is not involved in Fas-ligand-mediated apoptosis (although Hsp 27 is). Therefore, Hsp70 not only saves important components of the cell (the proteins) but also directly saves the cell as a whole.
=== Internment camps and Polish refugees === Thousands of Axis POWs and people described as "enemy aliens" were held in Southern Rhodesia during the conflict. These were mainly Italians and Germans, but there were also a handful from Iraq and the Levant; the colony furthermore hosted nearly 7,000 refugees from Poland. Britain delegated responsibility for co-ordinating investigation into enemy aliens in central Africa to the Southern Rhodesian government, which set up a system whereby the Criminal Investigation Department (CID) identified potential detainees while a body called the Internment Camps Corps oversaw the camps. Many of those held in Southern Rhodesia were sent there by Britain or authorities elsewhere in the Empire. Five internment camps were set up in two waves. No. 1 (General) Internment Camp opened to the north-east of Salisbury in October 1939 and No. 2 (Tanganyika) Internment Camp, just south of the city, opened the following year, mostly housing Germans formerly resident in Tanganyika. The first two camps together had less than 800 inmates. The third, fourth and fifth camps were set up near Gatooma, Umvuma and Fort Victoria in 1941–42 to accommodate roughly 5,000 Italians from Somaliland and Abyssinia. The Internment Camps Corps' reliance on the elderly, the infirm and so-called "friendly aliens" to staff the three new camps led to indiscipline, poor living conditions and dozens of escapes. A 1943 government commission into the quality of the internment camps reported the second wave camps to be of far worse quality than those of the first wave.
=== Infantry anti-tank weapons === PIAT – still in use in 1950s M20 Super Bazooka – Replaced PIAT. Domestically manufactured launchers and rounds were issued in addition to the American originals. Carl Gustaf 8.4cm recoilless rifle M72 LAW LAW 80 - first delivered in 1987, first issued to British Army of the Rhine in 1988
Eileen Dorothy Chambers, Member, Board of Visitors, Her Majesty's Prison and Young Offenders' Institution Drake Hall. For services to Prisoner Welfare. John Theng Keong Chan, Executive Officer, Department of Health. Stephen Victor Chandler, Constable, Metropolitan Police. For services to the Police. Captain Kandiah Chandran, lately Chief Executive, Presentation Housing Association. For services to the Housing Association Movement. Dipakkumar Govindji Chauhan. For services to Community Relations in Tameside, Manchester. Charles Peter Chivers. For services to the community in Cuddington, Cheshire. Alan Leslie Chorley, lately Treasurer, Access Committee for England. For services to disabled people. Celia Ruth Bonham Christie, Founder and Life President, Triumph Over Phobia. For services to the community. William Christie, . For services to the Royal Air Forces Association. Alan Ernest Clark, Senior Executive Officer, Acas, Department of Trade and Industry. Audrey Clark, lately Superintendent Registrar, Gateshead Metropolitan Borough Council. For services to the community. John Clark, Design Engineer, Royal Observatory, Edinburgh. For services to Astronomy. Joan Clarke, General Assistant, Dining Hall, Worcester College of Higher Education. For services to Education. Robert Clarke, Trident Boat Manager, VSEL. For services to the Defence Industry. Stephen Harold Henry Clarke. For services to Archaeology in Monmouth. Margaret Winifred Clarkson. For services to Carlisle Cathedral. Phyllis Mary Coates. For services to the community in Shere, Surrey. Elizabeth Cochrane.
The Assam Legislative Assembly is the unicameral legislature of the Indian state of Assam. The Legislative Assembly comprises 126 Members of Legislative Assembly, directly elected from single-seat constituencies. Its term is five years, unless sooner dissolved. Members of the Assembly are directly elected by the people of Assam through elections held every five years, unless the Assembly is dissolved earlier. The current Assembly was elected in April–May 2026, and the next election is scheduled for 2031. The Assembly plays a key role in law-making for the state, handling crucial matters such as state budgets, development policies, and local governance. It has the authority to legislate on issues specified under the State and Concurrent Lists of the Constitution of India. The Assembly functions through various committees that handle specific issues, including the budget, public accounts, and legislative procedures. The Chief Minister, who is the leader of the majority party in the Assembly, holds executive powers and is the head of the state government.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.